TABLE I.
Effects of SMFs on bone regeneration. Bone marrow mesenchymal stem cells (BMSCs); periodontal ligament stem cells (PDLSCs); Wharton's jelly mesenchymal stem cells (WJMSCs); mandibular condylar chondrocytes (MCCs); and N/A, not available.
| Objects | Magnetic flux density | Magnetic field direction | Exposure time | Effects on cell proliferation and differentiation | Effects | References | ||
|---|---|---|---|---|---|---|---|---|
| In vitro | Humans | BMSCs | 3, 15, and 50 mT | Upward | 21 days | Promotion | Promoted proliferation and osteoblast differentiation of human BMSCs | 18 |
| 50, 100, and 150 mT | Perpendicular | 12 h/day, 14 days | Promoted osteogenic differentiation of cells | 19 | ||||
| 100 mT | Upward | 28 days | Enhanced cell viability, DNA synthesis, and led to early transformation of the osteogenic lineage supported by Runx2 and ALP expression | 20 | ||||
| Perpendicular | 12 h/day, 1, 4, 7, and 14 days | Enhanced cell viability, proliferation and adhesion, improved cell morphology, and promoted osteogenic differentiation, possibly due to upregulation of the BMP-Smads signaling pathway | 33 | |||||
| 100, 200, 400, and 600 mT | 7, 14, and 21 days | Induction of chondrogenesis in BMSCs via TGF-β-dependent pathway | 21 | |||||
| PDLSCs | 320 mT | N/A | 14 days | Activation of the phosphorylated AKT pathway to enhance proliferation and osteogenic differentiation | 24 | |||
| WJMSCs | 400 mT | Increased matrix vesicle secretion and mineralization, enhanced osteogenic differentiation, but no effect on cell viability and growth | 34 | |||||
| Chondrocytes | 3 T | 1 and 96 h | Inhibition | Suppressed cell growth and induced apoptosis through p53, p21, p27, and Bax protein expression | 25 | |||
| Rats | Calvaria cell | 160 mT | N/A | 20 days | Promotion | The values of the total area and the number and average size of bone nodules showed high levels, the calcium content in the matrix and alkaline phosphatase and OCN also showed a significant increase | 14 | |
| Mandibular BMSCs/MCCs | 280 mT | Vertical | 14 days | Improved chondrogenesis and proliferation of Mandibular BMSC in the co-culture system | 22 | |||
| MCCs | N/A | Enhanced differentiation through FLRT/BMP signaling | 23 | |||||
| Mice | Osteoblast MC3T3-E1 | 500 nT, 200 mT, and 16 T | Upward and downward | 10 days | Promotion/inhibition | 16 T SMF increased osteoblast differentiation, 500 nT and 200 mT SMFs decreased osteoblast differentiation | 12 | |
| Raw264.7 | N/A | 500 nT and 200 mT SMFs promoted the differentiation, formation, and resorption of osteoclast Raw264.7, whereas a 16 T SMF acted as an inhibitor | 13 | |||||
| 1–2 T | 4 days | Inhibition | Osteoclast formation in the presence of Ferumoxytol was reduced | 15 | ||||
| Osteoblast MC3T3-E1 | 8 T | Parallel | 14 days | Promotion | Stimulated bone formation to grow in the direction of the magnetic field | 16 | ||
| 60 h | 17 | |||||||
| In vivo | Rats | Whole animal | 4 mT | ⋯ | 16 weeks | Prevented bone architectural deterioration and strength reduction | 30 | |
| 30–200 mT | Parallel | 12 weeks | Increased bone density and bone area | 31 | ||||
| 100 mT | N/A | 12 h/day, 6 and 12 weeks | Enhanced bone regeneration and osseointegration | 19 | ||||
| 180 mT | 6 weeks | Significantly increased bone mineral density | 32 | |||||
| 12 weeks | Prevented the decrease in bone mineral density | 26 | ||||||
| Mice | 200 mT | Alternating magnetic poles | 2 weeks | Stimulated chondrogenesis, enhanced the cellular matrix of cartilage and increased endogenous stem cell migration | 27 | |||
| 200–400 mT | Downward | 4 weeks | Increased of bone resorption in reloaded mice | 28 | ||||
| 2–4 T | N/A | 28 days | Promoted bone formation, increased osteoblasts, and reduced the number of osteoclasts | 29 | ||||